Skip to main content

Closed

LCTX: Lineage Cell Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Operating margin-255.1%

ROIC-34.1%

Financially safe

Stretched

Debt / equity0.04×

Interest coverage0.0×

Current ratio6.89×

Lineage Cell Therapeutics, Inc.

LCTXNew York Stock Exchange Arca·USD·Closed

Lineage Cell Therapeutics, Inc.

LCTXNew York Stock Exchange Arca·USD·Closed

$1.08

−2.70%

$1.08

−$0.03 (2.70%)

52W Range

11thpctl

Volume

0.58×avg

Mkt Cap

269.24MUSD

P/E

-3.9TTM

Div Yield

–ann

52W Range

11thpctl

Volume

0.58×avg

Market Cap

269.24MUSD

P/E Ratio

-3.9TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings